How to buy Aduro Biotech stock

Aduro Biotech Inc is a biotechnology business based in the US. Aduro Biotech shares (ADRO) are listed on the NASDAQ and all prices are listed in US Dollars. Aduro Biotech employs 69 staff and has a trailing 12-month revenue of around 0.00.

Aduro Biotech stock price (NASDAQ: ADRO)

Use our graph to track the performance of ADRO stocks over time.

Aduro Biotech shares at a glance

• Key figures

Information last updated 2020-11-22.

52-week range	$0.00 - $0.00
50-day moving average more info button	$3.71
200-day moving average more info button	$2.91
Wall St. target price	$18.75
PE ratio more info button	N/A
Dividend yield more info button	N/A (0%)
Earnings per share (TTM) more info button	$-1.15

Buy Aduro Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aduro Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Aduro Biotech stock undervalued or overvalued?

Valuing Aduro Biotech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aduro Biotech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Aduro Biotech's PEG ratio

Aduro Biotech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.06. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Aduro Biotech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Aduro Biotech financials

Revenue TTM	$28 million
Gross profit TTM	$-48,610,000
Return on assets TTM	-13.9%
Return on equity TTM	-87.44%
Profit margin	-230.92%
Book value	$2.88
Market capitalisation more info button	$236.6 million

TTM: trailing 12 months

Aduro Biotech share dividends

We're not expecting Aduro Biotech to pay a dividend over the next 12 months.

Have Aduro Biotech's shares ever split?

Aduro Biotech's shares were split on a 1:5 basis on 1 October 2020. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aduro Biotech shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Aduro Biotech shares which in turn could have impacted Aduro Biotech's share price.

Aduro Biotech share price volatility

Over the last 12 months, Aduro Biotech's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aduro Biotech's is 0.3861. This would suggest that Aduro Biotech's shares are less volatile than average (for this exchange).

Aduro Biotech overview

Aduro Biotech, Inc. , an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B. V.

Frequently asked questions

What percentage of Aduro Biotech is owned by insiders or institutions?
Currently 29.837% of Aduro Biotech shares are held by insiders and 44.755% by institutions. How many people work for Aduro Biotech?
Latest data suggests 69 work at Aduro Biotech. When does the fiscal year end for Aduro Biotech?
Aduro Biotech's fiscal year ends in December. Where is Aduro Biotech based?
Aduro Biotech's address is: 740 Heinz Avenue, Berkeley, CA, United States, 94710-2224 What is Aduro Biotech's ISIN number?
Aduro Biotech's international securities identification number is: US16961L1061 What is Aduro Biotech's CUSIP number?
Aduro Biotech's Committee on Uniform Securities Identification Procedures number is: 00739L101